Paolo Tarantino: What is the activity of different treatment regimens after progression on T-DXd for MBC?
Paolo Tarantino, Research fellow at Dana-Farber Cancer Institute, posted on X:
“What is the activity of different treatment regimens (SG, cape, eribulin…) after progression on T-DXd for MBC? Come find out at our poster P1-08-08. Collaboration between Dana-Farber Cancer Institute and Yale University.”
Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan. His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023